Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests; full year volume of 16,233 tests outperforms initial 2025 projectionsStrong cash position of approximately $240 million provides capital for commercial expansionSecured pivotal Medicare coverage for breast cancer surveillance, validating ultrasensitive MRD technologyPreliminary Q4 revenue of $17 to $18 million; preliminary full year revenue of $69 to $70 million FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025.Fourth Quarter Strategic and Operational HighlightsSecured Milestone Medicare Coverage: Received Medicare coverage approval for the surveillance of cancer recurrence in breast cancer patients, a key catalyst for clinical revenue and market share growth in the MRD space.Published Landmark TRACERx Data: Annou
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ [Yahoo! Finance]Yahoo! Finance
- Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™Business Wire
- Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $12.00 price target on the stock.MarketBeat
- Personalis (NASDAQ:PSNL) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PSNL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</MarketBeat
- Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) [Yahoo! Finance]Yahoo! Finance
PSNL
Earnings
- 11/4/25 - Beat
PSNL
Sec Filings
- 1/8/26 - Form SCHEDULE
- 1/8/26 - Form 8-K
- 11/28/25 - Form 8-K
- PSNL's page on the SEC website